List of Excipients in API nivolumab
✉ Email this page to a colleague
Detailed excipient profiles for nivolumab
Excipient focus: HISTIDINE
nivolumab drug variants containing HISTIDINE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing HISTIDINE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| >Company | >Ingredient | >NDC |
Excipient focus: HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE
nivolumab drug variants containing HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
nivolumab drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
nivolumab drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
Excipient focus: METHIONINE
nivolumab drug variants containing METHIONINE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing METHIONINE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
Excipient focus: PENTETIC ACID
nivolumab drug variants containing PENTETIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing PENTETIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
nivolumab drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CHLORIDE
nivolumab drug variants containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
nivolumab drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
Excipient focus: SUCROSE
nivolumab drug variants containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| >Company | >Ingredient | >NDC |
Excipient focus: TRISODIUM CITRATE DIHYDRATE
nivolumab drug variants containing TRISODIUM CITRATE DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing TRISODIUM CITRATE DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
nivolumab drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | nivolumab | 0003-3772 |
| ER Squibb & Sons LLC | nivolumab and hyaluronidase-nvhy | 0003-6120 |
| ER Squibb & Sons LLC | nivolumab and relatlimab-rmbw | 0003-7125 |
| >Company | >Ingredient | >NDC |
nivolumab drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch